Back to results
US 2020/0206129 A1Published application
Formulations for intravenous administration
AssigneeGlaxosmithkline Intellectual Property (No.2) Limited
InventorsRachel Apfelbaum, Andrew James Peat, Yoon Oh
Life of this patent
Estimating the term…
Abstract
The present invention relates to an improved formulation of danirixin in its hydrobromide salt form. This improved formulation can be an aqueous intravenous formulation containing danirixin or a lyophilized pharmaceutical solid composition containing danirixin to be reconstituted to provide a solution for intravenous administration.
Claims18
A pharmaceutical composition comprising:
- danirixin in its hydrobromide salt form;
- and one or more pharmaceutically acceptable excipients comprising mannitol.
A pharmaceutical composition comprising:
- danirixin in its hydrobromide salt form;
- and one or more pharmaceutically acceptable excipients comprising sulfobutyl ether-β-cyclodextrin.
A pharmaceutical composition comprising:
- danirixin in its hydrobromide salt form;
- and one or more pharmaceutically acceptable excipients comprising:
- sulfobutyl ether-β-cyclodextrin, mannitol, and a citrate buffer.
Dependencies are inferred from the claim text.